Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery

Abbott Laboratories (NYSE:ABT) is one of the 10 best healthcare equipment stocks to buy according to hedge funds.

On February 2, the price target on Abbott Laboratories (NYSE:ABT) was reduced from $169 to $142 by Barclays analyst Matt Miksic. The analyst reiterated his Overweight rating on the stock, which offers a revised upside potential of almost 27%.

Miksic’s revisions were based on deflated forecasts and target multiple for the stock, in line with the company’s own outlook. However, he expects the ongoing struggles across the nutrition and diagnostics segments to improve during 2026.

Back on January 23, Lee Hambright from Bernstein reaffirmed an Outperform rating on Abbott Laboratories (NYSE:ABT). The analyst lowered the price target from $154 to $125, which still leads to a low double-digit upside of almost 12%.

Hambright noted that the company’s fourth quarter topline figures of $11.46 billion exhibited 3% organic growth despite missing consensus forecasts by 3%. The Nutrition segment dropped 9% to $1.94 billion, missing the estimates by 12%. This accounted for 75% of the total sales miss for the quarter.

Abbott Laboratories (NYSE:ABT) is a leading name in the healthcare industry that is involved in the discovery, development, and marketing of healthcare products across the globe. The business is segregated into four segments, i.e., Diagnostic Products, Established Pharmaceutical Products, Medical Devices, and Nutritional Products.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.